Pulmonary Function Testing (PFT) is an essential tool in the diagnosis and management of respiratory diseases. However, the interpretation of these tests can be complex, requiring a comprehensive understanding of respiratory physiology. This article aims to provide a concise guide to PFT interpretation for healthcare professionals.
Standard PFTs comprise of spirometry, lung volumes, and diffusion capacity. Spirometry measures the volume and speed of air that can be inhaled and exhaled, providing vital information on airflow limitation. Lung volumes assess the total capacity of the lungs, while diffusion capacity evaluates the efficiency of gas transfer from the lungs to the blood.
Spirometry results are interpreted by comparing the patient's values to predicted normal values. A reduced ratio of forced expiratory volume in 1 second (FEV1) to forced vital capacity (FVC) suggests obstructive disease, such as asthma or COPD. A reduced FEV1 and FVC with a normal FEV1/FVC ratio points towards restrictive disease, like pulmonary fibrosis.
Lung volumes can provide additional information when spirometry is inconclusive. An increased residual volume (RV) can indicate air trapping, common in obstructive diseases. A reduced total lung capacity (TLC) is suggestive of restrictive disease. The diffusion capacity of the lung for carbon monoxide (DLCO) is useful in diagnosing and monitoring conditions that affect gas exchange, such as emphysema or pulmonary hypertension.
PFT interpretation is a critical skill for healthcare professionals involved in respiratory care. A systematic approach to interpreting spirometry, lung volumes, and diffusion capacity can facilitate accurate diagnosis and guide treatment decisions. Continuing education and practical experience are key to mastering PFT interpretation.
1.
Researchers use genomic technology to investigate aggressive skin cancer linked to burn scars
2.
The Growing Role of AI in Cancer Treatment
3.
Tafasitamab Regimen Improves PFS in Relapsed/Refractory Follicular Lymphoma
4.
Lower Prostate Cancer Mortality Linked to Unavailable Clinical Trials.
5.
Powerlifting through breast cancer: How a breast cancer survivor defied chemotherapy with strength training
1.
Drug Exposure in Tumor Microenvironments: Mechanisms, Clinical Implications, and Emerging Strategies
2.
Proteoform Networks in Blood Disorders: Mechanisms, Clinical Implications, and Emerging Therapeutic Strategies
3.
Antibody-Drug Conjugates and the Dawn of Targeted Cancer Therapy in 2025
4.
Revolutionizing Oncology Trials: Optimization, Matching, Diversity, and Decentralization
5.
Direct Oral Anticoagulants (DOACs) in Atrial Fibrillation: A Comprehensive Review
1.
International Conference on Innovations in Critical Care for Oncology and Cardiology
2.
International Conference on Oncology, Cardiology and Critical Care Policy
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
1.
An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion- Part II
2.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part IV
3.
Targeting Oncologic Drivers with Dacomitinib: A New Approach to Lung Cancer Treatment
4.
How Multidisciplinary Teams Support Modern Cancer Care
5.
Influence of CDK4/6 Inhibitors in Extending Progression-Free Survival (PFS) and Overall Survival in HR+/HER2- mBC Patients
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation